Alessandro Maselli’s Post

Excited for the 7th Alcor Drug Discovery Platform Summit under the esteemed leadership of our Chairman for Day 1, Abdulkader Rahmo, who serves as President & CSO SMSbiotech. As we convene for this premier event, we embark on a collective journey of exploration, collaboration, and innovation in the dynamic realm of drug discovery. Under Chairman Rahmo's visionary guidance, this summit promises to be a nexus of cutting-edge research, insightful discussions, and invaluable networking opportunities. Join us as we unite with leading experts, industry pioneers, and visionaries to chart the course for the future of drug discovery. This summit isn't just about presentations—it's a convergence of minds dedicated to driving progress, shaping the future, and making a meaningful impact on global health. Let's elevate the discourse, ignite innovation, and propel the field of drug discovery to new heights. Together, we're shaping a healthier, brighter tomorrow. #AlcorDrugDiscovery #Summit #Innovation #ADDP2024 #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits  #DrugDiscoverySummits #EuropeanClinicalTrialSummits #Scientist #DrugDiscovery #Preclinical #Medchem #Biology #Protein #Antibodies #Conference #InPersonEvent #Summit #AI ML #Data #Oncology #DrugDevelopment #Collaboration #Keynote #PanelDiscussion #Oncology #Therapeutics #DrugDesign #SmallMolecules #LargeMolecules #Events #Therapeutics #BigData #Marketing #DigitalMarketing #AIdrug

If Roche is inefficient in its R&D, does it mean more opportunities for small, research-based biotech firms? The Zurich Sunday paper (NZZ am Sonntag) wrote a full-page article on Roche's faltering R&D. Despite investing staggering piles of cash (CHF 11 billion in 2023) into research, quoted insiders say the company's development pipeline is practically empty – particularly in its core business, oncology. The article blames an outdated organizational structure: In addition to the Basel headquarters, Roche has an important R&D center in San Francisco, and apparently this leads to redundancies. Roche itself refuses this interpretation and assures it has no plans to merge its research units. I'm no expert in giant corp org structures, so I won't claim to have a hot take on that topic. Or maybe my hot take is that I'm glad I don't have to live with and work in a convoluted giant corp org structure... Except that a lot of small medtech and life science companies will, in fact, need to navigate these structures, as they often collaborate with giants like Roche. And my heart beats for these small companies. I wonder what impact Roche's lagging will have on medical research in general and cancer therapies in particular. I mean, we DO have a ton of small companies working in the field. Can up-and-coming biotech fill a gap left by a giant like Roche? Is that what's already happening? Or do they stand and fall with the deep pockets of big pharma? Asking for a friend. (Sorry if you were expecting an answer from me – ain't got one today.)

Seoul, South Korea, July 30, 2024 – Lmito Therapeutics announced today that, effective June 1, 2024, it has become a member of Johnson & Johnson Innovation – JLABS Korea. The company is working toward developing novel therapies for immunological disorders through an emerging concept of metabolic reprogramming. Lmito's groundbreaking technology focuses on modulating immunometabolisms in the inflammation microenvironment (IME). This approach has shown promise in promoting anti-inflammatory responses and reducing fibrosis, offering a dual-action approach to simultaneously address inflammation and fibrosis. By targeting these key aspects of disease progression, Lmito aims to develop more effective and safer treatments for patients suffering from chronic inflammatory and fibrotic conditions. "We are thrilled to join as an inaugural member of JLABS Korea as it marks a significant milestone in Lmito's journey," remarked Wheeseong Lee, CEO of Lmito. "The JLABS network will provide us with world-class mentorship and invaluable resources and research capabilities to accelerate Lmito's innovative approach in developing therapies for a spectrum of autoimmune diseases." The company's membership of JLABS Korea will leverage the expertise and global reach of Johnson & Johnson and the track record of JLABS in accelerating innovation across the globe. We aim to connect within innovative circles and create pathways to potential pharmaceutical industry partnerships, positioning Lmito at the forefront of biotechnological advancement. About Lmito: Lmito is a biotechnology company pioneering the modulation of cell metabolisms in the inflammation, fibrosis, and tumor microenvironments to develop innovative therapies for autoimmune diseases, fibrosis, and cancer, respectively. This innovative strategy targets critical aspects of various chronic diseases, addressing the pressing need for more effective treatments with fewer side effects in multiple conditions. By leveraging its expertise in metabolic reprogramming, Lmito aims to transform the treatment landscape for patients with limited therapeutic options. https://lnkd.in/gYbn9ZZ9.

“Knowledge of what causes human disease has exploded in the ‘omics’ era, but the ability to discover and develop new molecules to treat those diseases hasn't kept pace,” said Terray Therapeutics CEO and co-founder Jacob Berlin, PhD. “Trained on rapidly iterating, precise data generated at unprecedented scale in our labs, Terray’s AI will dramatically improve the success rate of small molecule development and bring relief to patients.” Terray Therapeutics has just secured an additional $120M in #SeriesB funding (bringing its total equity financing since inception to over $200M) to propel its small molecule programs forward. In an industry where precision and speed in drug development are paramount, Terray’s AI-powered platform offers a new approach to addressing the challenges of traditional discovery methods. This milestone comes with the backing of key investors like NVIDIA and Bristol Myers Squibb, who clearly see the transformative potential in this partnership. Together, they aim to tackle the bottlenecks in traditional drug discovery, combining Terray’s proprietary AI technology with the expertise of industry heavyweights. Other milestones include: ✅ Rapid progress on internal immunology programs, driven by AI-powered chemistry optimization. ✅ Strategic partnerships with Calico Life Sciences and Bristol Myers Squibb to address complex disease targets. ✅ Development and publication of the industry-leading COATI chemistry foundation model and the application of latent diffusion machine learning for small molecule design—a first in the field. ✅ Strenghtened leadership at Terray with the addition of experienced figures such as Feroze U. (Fez Ujjainwalla) as Chief Business Officer and Anna Goranson as Chief People Officer. Additionally, biotech veterans like John Maraganore, Bassil Dahiyat, and Sudha Parasuraman have taken on strategic roles within the company, further solidifying its leadership position in the industry. Bedford Ridge Capital nVentures Maverick Capital Goldcrest Capital Madrona Venture Labs Two Sigma XTX Ventures Digitalis Ventures Sid Shenai Kimberly Powell #Biotech #AIinHealthcare #DrugDevelopment #TerrayTherapeutics #SmallMolecule #PrecisionMedicine #BiopharmaInnovation #Biopharma #Innovation

Exciting news in the biotech world! Recursion and Exscientia are merging to create a powerhouse with $850 million in cash and a pipeline set to deliver 10 clinical readouts over the next 18 months! This merger brings together Recursion's strengths in biology and Exscientia's cutting-edge chemistry capabilities, creating a complementary AI-driven platform poised to revolutionize drug discovery. Despite initial challenges, the combined company is set to become an industry leader with its innovative approach and financial stability, aiming to fund operations well into 2027. The future of medicine looks bright! 🌟 #Biotech #Innovation #AI https://lnkd.in/eM-meDA4

This week we hosted leading figures in UK biopharma to share how the PrecisionLife #CausalAI platform is improving the probability of success in drug discovery, clinical development, and product launch. Thank you to everyone who joined us at Babraham Research Campus to help overcome some of the biggest challenges facing drug developers today. By gaining a better understanding of causal biology and pioneering mechanistic biomarker-driven R&D, we're informing and de-risking key stages of drug discovery and development. Creating precision medicines for complex, chronic diseases to improve the lives of billions of people. If you weren't able to be there in person and would like to know more, get in touch with the PrecisionLife team at https://lnkd.in/eaTtCDgH 📸 1️⃣ - Steve Gardner presents our platform enabling the discovery, development, and launch of precision medicines 2️⃣ - Rowan Gardner shares how unknown causal biology is the root of major drug development risk and healthcare inefficiency 3️⃣ - Sayoni Das provides examples of our precision medicine-ready programs 4️⃣ - Steve explains what is now possible with unprecedented insights into patient biology and the molecular mechanisms of their disease 5️⃣ - Steve and Sayoni demonstrate how mechanism-based biomarkers are accelerating and de-risking clinical development 6️⃣ - Precision Medicine in Chronic Diseases: Increasing Probability of R&D Success with Causal AI - visit precisionlife.com for more.

Navigating the highly-complex SAR landscape when doing drug design is challenging. Looking forward to the collaboration mentioned below, aiming to accelerate the delivery of differentiated therapeutics and get valuable learnings along the way.

Get ready to embrace curiosity in just 2 weeks! At this year's #SwissBiotechDay, hosted by the esteemed Swiss Biotech Association and renowned as one of Europe's premier #biotechnology #conferences, Bavarian Biotech is set to take center stage at the 🏘️ #globalvillage. The Swiss Biotech Day serves as a nexus for professionals within the 🌎global #lifesciences community, drawing in experts from diverse backgrounds. In 2024, it promises yet another immersive experience, offering a fertile ground for #networking, thought-provoking discussions, and the exploration of cutting-edge advancements across various domains such as #R&D, manufacturing, data management, #artificialintelligence, and innovative #financing. We extend a warm invitation for you to connect with the Biotech companies from #Bavaria featured in this year's #BioMdelegation. Join us as we embark on this journey, with the following #pioneers on board: 👉 FGK Clinical Research GmbH: A full service contract #research organisation (#CRO) offering a complete range of clinical development and consulting services to pharmaceutical, biotechnology and #medicaldevice companies. 👉 Iris Biotech GmbH provides scientists in both industry and academia with innovative and rare #compounds, standard consumables and unusual building blocks i.e. required for the modification of #peptides. 👉 Cfm Oskar Tropitzsch GmbH assists the chemical, #pharmaceutical and biotechnological industry in sourcing and producing #chemical specialties – with the right documentation, the correct quantity from mg to mt and proper quality. 👉 Cortex Discovery’s in silico #drugdiscovery platform is based on its leading-edge #AI technology which can predict molecule properties in all therapeutic fields. Cortex’s comprehensive services cover the entire spectrum of preclinical #drugdevelopment, from #HitDiscovery to #LeadOptimization. 👉 Velvio GmbH develops new medicines to restore organ repair functions for treatment in #Neurodegeneration and Pulmonary Fibrosis, first in #Orphandiseases Amyotrophic Lateral Sclerosis (ALS) and Idiopathic pulmonary Fibrosis (IPF). Furthermore, Velvio targets to enhance clinical responses of solid tumors to #Immune-#Oncology treatment concepts. We are looking forward to meeting you in #Basel! #swissbiotechday2024

Online Now: Preclinical assessment for translation to humans: The PATH approach for assessing supporting evidence for early-phase trials and innovative care http://dlvr.it/TCjWj8

We're proud to add Alpha Cognition, Inc. (CNSX: $ACOG) to the roster of quality presenting companies at the upcoming B2i Digital Featured Conference: Spartan Capital Securities, LLC Investor Conference 2024. The event is scheduled for November 4th at The Pierre Hotel in New York City. Alpha Cognition, Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative disease, such as Alzheimer’s disease and Cognitive Impairment with mild Tramautic Brain Injury (“mTBI”). The Company’s first product ZUNVEYL is approved by the U.S. Food and Drug Administration (FDA) as a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Alpha Cognition, Inc. initiatives are spearheaded by Denis Kay, Phillip Mertz, Michael Mcfadden, and Don Kalkofen. Conference attendees will have the unique opportunity to engage directly with Alpha Cognition, Inc. executives, gaining valuable insights into the company’s development in novel treatments for under-served neurodegenerative diseases. The Spartan Capital Investor Conference brings together an impressive array of public company executives, institutional investors, and thought leaders in the U.S. capital markets. With over 30 companies slated to present, the event promises unparalleled networking opportunities. For those interested in attending this exclusive event, please submit a request to participate at https://lnkd.in/e6ZQhZyA Kindly note that attendance is limited and subject to approval. Thank you to our hosts at Spartan Capital who made this event possible: John D. Lowry, Kim Monchik, Joe Giamichael, Stephen Faucetta, Julia Voss, William Birney, Donald Powell, Louis Valdez, Abdiell (AJ) Suero, Blake Weltmann, Ralph Metz and many others. Spartan Capital Securities, LLC is a full-service, integrated financial services firm trusted by high-net-worth individuals and institutions for sound investment guidance. We focus on understanding our clients' objectives and executing strategies to meet their financial goals. #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024 #AlphaCognition #ACOG #biopharmaceutical